Since its founding days, immatics has fueled its growing business by partnering with academic institutions, hospitals, consulting companies and other businesses.
At present, the growing pipeline of tumor-specific antigens and antigenic peptides identified by immatics offers numerous opportunities for co-development of our product candidates by pharmaceutical and biotech companies.
Biopharmaceutical companies with a focus on oncology and strong interests especially in the fields of clinical development of active immunotherapy are welcome to contact us for finding out more about partnerships for co-development.
